Etoposide
Mature T-Cell And NK-Cell Non-Hodgkin Lymphoma
Explore 36 assets in Mature T-Cell And NK-Cell Non-Hodgkin Lymphoma →Floatz Rating
BB70/100
Confidence
Indicative
Sponsor
Alliance for Clinical Trials in Oncology
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
62High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04803201CT.gov Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma | — | Suspended | — | — | — |
NCT04999878CT.gov A Prospective Clinical Study of Ruxolitinib and Etoposide Combined With DDGP Regimen (RUE-DDGP) in Induction Therapy of T/NK Cell Lymphoma-associated Hemophagocytic Syndrome. | — | Unknown | — | — | — |
NCT02342782CT.gov Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma | — | Completed | — | — | — |
NCT03113500CT.gov Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT02797470CT.gov Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant | — | Active Not Recruiting | — | — | — |
NCT02223208CT.gov Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas | — | Active Not Recruiting | — | — | — |
NCT01897012CT.gov Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas | — | Completed | — | — | — |
NCT01567709CT.gov Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma | — | Completed | — | — | — |
NCT01466881CT.gov Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma | — | Completed | — | — | — |
NCT00697346CT.gov Study of MLN8237 in Participants With Advanced Hematological Malignancies | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Mature T-Cell And NK-Cell Non-Hodgkin Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Etoposide (this asset) | Alliance for Clinical Trials in Oncology | Approved | BB · 70 |
| Cyclophosphamide | City of Hope Medical Center | P2 | BB |
| Dexasone | Zhengzhou University | P4 | BB |
| Nivestim | City of Hope Medical Center | P2 | BB |
| (+)-Vincristine | City of Hope Medical Center | P2 | BB |
| Prednisone | City of Hope Medical Center | P2 | BB |
| Adriamycin | City of Hope Medical Center | P2 | BB |
| Lenalidomide | National Health Research Institutes, Taiwan | P1/2 | BB |
| Cis-Diamminedichloroplatinum Ii | Zhengzhou University | P4 | BB |
+42 more in the Mature T-Cell And NK-Cell Non-Hodgkin Lymphoma cohort
Other indications for Etoposide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Megakaryoblastic Leukemia | — | P3 | BBB · 79 |
| Acute Monocytic Leukemia | — | P3 | BBB · 79 |
| Acute Myeloblastic Leukemia With Maturation | — | P3 | BBB · 79 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Etoposide in Mature T-Cell And NK-Cell Non-Hodgkin Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/etoposide-mature-t-cell-and-nk-cell-non-hodgkin-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →